Evidence map›Paper›PMID 40985995›Full record

ArticleClinical and translational medicine2025

CD103

Tianyi Zhang, Junquan Song, Yinlam Li, Kangjie Shen, Jiangying Xuan, Yuan Gao, Lili Lu, Zhi Pang, Lu Wang, Yang Yang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. CD39 on CD8European journal of immunology · 2026
    Review
  2. The Proximity of PD-1Cancers · 2026
    Article
  3. Review
  4. CD103Clinical and translational medicine · 2025
    Article
  5. Multi-omics spatial characteristics of CD8Frontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tianyi ZhangDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.ORCID 0009-0003-5560-774X
Junquan SongDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Yinlam LiDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Kangjie ShenDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Jiangying XuanDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Yuan GaoDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Lili LuClinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Zhi PangClinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Lu WangDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Yang YangDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Zixu GaoDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Qianrong HuDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Yu ZhuDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Chenlu WeiDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Shaoluan ZhengDepartment of Plastic and Reconstructive Surgery, Zhongshan Hospital (Xiamen), Fudan University, Shanghai, PR China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Yuhong ZhouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Chuanyuan WeiDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Jianying GuDepartment of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.ORCID 0000-0002-7870-103X

Funding

China Postdoctoral Science Foundation 2022M710769China Postdoctoral Science Foundation 2022TQ0072National Natural Science Foundation of China 81972559National Natural Science Foundation of China 82203528National Natural Science Foundation of China 82272891National Natural Science Foundation of China 82473001Shanghai Municipal Health Commission Collaborative Innovation Cluster Project 2024CXJQ02Shanghai Sailing Program 22YF1407400
6 · The paper itself

Abstract

backgroundImmunotherapy has revolutionised melanoma treatment, providing significant clinical benefits by reactivating the anti-tumour immune system. CD8

methodsFollowing CD8

resultsCD8

conclusionsCD103 KEY POINTS: CD103 is a reliable marker of tissue-resident memory (TRM) CD8

Indexed as

Antigens, CDCD8-Positive T-LymphocytesImmunotherapyIntegrin alpha ChainsMelanomaMemory T CellsAnimalsFemaleHumansMicealpha E integrinsAntigens, CDIntegrin alpha ChainsimmunotherapymelanomaTILtissue‐resident memory T lymphocytes

Identifiers

PMID40985995
PMCPMC12456097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.